Private equity firm EQT is acquiring in-silico drug development service provider Certara from Arsenal Capital Partners, a deal that values the CRO at $850 million, Arsenal announced on Tuesday.
Arsenal will retain an unspecified minority stake in Certara, and the company’s current management team, including CEO Edmundo Muniz, M.D., Ph.D., who joined the company in June 2014 from Kirax, will stay on.
Certara is known for its drug development modeling software and regulatory services. Founded in 2008 from a merger between drug discovery informatics provider Tripos and clinical software and regulatory services specialist Pharsight, the company’s current expertise was built through a series of seemingly ceaseless acquisitions:
Thanks to its acquisitions, the services provided by the Princeton, New Jersey-based CRO now span from physiologically based pharmacokinetic modeling and simulation to pharmacometrics to commercial optimization and regulatory writing.
The company, through 19 offices in four continents, serves 1,200 commercial companies, 250 academic institutions and almost all major regulatory agencies. More than 500 employees work for the company, with 100 scientists in in-silico drug development practice and 120 in the regulatory writing section.
This marks EQT’s second major investment in the U.S. healthcare sector, following a $2.35 billion deal to buy up Press Ganey Holdings, a provider of patient satisfaction surveys, according to Reuters.
The CRO realm is nothing short of dealmaking these days, witnessing such megamerger deals as the $7.4 billion union between InVentiv Health and INC Research, and $17.6 billion between Quintiles and IMS Health. Parexel is also being taken private by Pamplona Capital Management for around $5 billion, a deal announced in late June.
By Angus Liu
Source: Fierce Biotech
Giovanni Caforio, the former CEO of Bristol Myers Squibb, is set to become the next board chairman of Novartis, which on Tuesday proposed the pharmaceutical industry veteran as its pick to replace Joerg Reinhardt in the role next year. Reinhardt has served as Novartis’ chair since 2013 and plans to retire when his 12-year term ends in 2025.
GE HealthCare has raised the curtain on two ultrasound systems equipped with artificial intelligence programs designed to assist in diagnosing conditions in women’s health, including obstetric exams. The Voluson Signature 20 and 18 imaging systems include AI tools capable of automatically identifying and annotating measurements of fetal anatomy.
Scientists from the University of Edinburgh’s School of Chemistry have revealed a new sustainable method of manufacturing complex molecules that could reduce waste produced during drug production. The method published in Nature Chemistry could help to prevent severe side effects caused by drugs that can exist as enantiomers.